Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 6/20 | 0.57 |
| ▸ | ST14 | Q9Y5Y6 | 5/20 | 0.57 |
| ▸ | F10 | P00742 | 13/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25015731 | 0.92 | ST14 (0.52) | F2ST14F10PRSS1PRSS2 | |
| SCHEMBL28573730 | 0.90 | F2 (0.50) | F2ST14F10PRSS1 | |
| SCHEMBL28573728 | 0.90 | F2 (0.50) | F2ST14F10PRSS1 | |
| SCHEMBL25017373 | 0.90 | F10 (0.46) | F2ST14F10PRSS1ITGB3 | |
| SCHEMBL25016673 | 0.88 | F2 (0.44) | F2ST14F10PRSS1ITGB3 | |
| SCHEMBL25016210 | 0.88 | F2 (0.44) | F2ST14F10PRSS1ITGB3 | |
| SCHEMBL28579688 | 0.88 | F2 (0.48) | F2ST14F10PRSS1PRSS2 | |
| SCHEMBL25015989 | 0.87 | F2 (0.50) | F2ST14F10PRSS1PRSS2 | |
| SCHEMBL25016626 | 0.86 | F2 (0.48) | F2ST14F10PRSS1PRSS2 | |
| SCHEMBL25015887 | 0.86 | ST14 (0.51) | F2ST14F10PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | MMP7, MATR3, SPINT2 | F2 408/4885ST14 150/4885F10 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.